Zacks: Brokerages Anticipate Cassava Sciences Inc (NASDAQ:SAVA) to Post -$0.06 EPS
Brokerages expect Cassava Sciences Inc (NASDAQ:SAVA) to post earnings per share (EPS) of ($0.06) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Cassava Sciences’ earnings. Cassava Sciences also reported earnings per share of ($0.06) during the same quarter last year. The firm is scheduled to announce its next earnings results on Monday, August 10th.
On average, analysts expect that Cassava Sciences will report full-year earnings of ($0.26) per share for the current fiscal year. For the next fiscal year, analysts anticipate that the firm will post earnings of $0.90 per share. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Cassava Sciences.
Cassava Sciences (NASDAQ:SAVA) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.05) earnings per share (EPS) for the quarter.
Shares of Cassava Sciences stock traded down $5.99 on Friday, hitting $2.12. The stock had a trading volume of 47,175,674 shares, compared to its average volume of 2,834,354. The stock has a 50 day moving average of $6.17 and a 200 day moving average of $5.07. Cassava Sciences has a twelve month low of $1.02 and a twelve month high of $10.95. The firm has a market capitalization of $200.97 million, a P/E ratio of -9.22 and a beta of 3.28.
Institutional investors have recently bought and sold shares of the business. Jefferies Group LLC bought a new position in shares of Cassava Sciences during the 4th quarter worth approximately $364,000. Marshall Wace LLP bought a new position in shares of Cassava Sciences during the 4th quarter worth approximately $284,000. Jane Street Group LLC boosted its holdings in shares of Cassava Sciences by 23.4% during the 4th quarter. Jane Street Group LLC now owns 17,269 shares of the company’s stock worth $90,000 after buying an additional 3,279 shares in the last quarter. Acadian Asset Management LLC bought a new position in shares of Cassava Sciences in the 4th quarter worth $79,000. Finally, Cetera Advisor Networks LLC bought a new position in shares of Cassava Sciences in the 4th quarter worth $109,000. Hedge funds and other institutional investors own 18.59% of the company’s stock.
About Cassava Sciences
Cassava Sciences, Inc, a clinical-stage drug development company, develops drugs for nervous system disorders. The company's lead therapeutic product candidate PTI-125, a small molecule drug that is in Phase II clinical trial for the treatment of Alzheimer's disease. It is also developing PTI-125Dx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
See Also: How to calculate compound interest
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cassava Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cassava Sciences and related companies with MarketBeat.com's FREE daily email newsletter.